XEN Gel Stent

Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Evolution in glaucoma surgery mounting with MIGS proceduresAn expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.
Managing glaucoma with surgical procedures (plural)The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
Innovative material helps implant lower IOP safely, effectivelyThe XEN Gel Stent is a micro-fistula implant designed to lower IOP without relying on physiologic outflow pathways – it connects the anterior chamber to the subconjunctival space. Prospective data from more than 900 surgeries from around the world support the safety and efficacy of this device.
Advances in minimally invasive glaucoma surgeryOne surgeon’s experiences with the iStent trabecular micro bypass; an implant that forms a patent opening through the trabecular meshwork into Schlemm’s canal, restoring physiological aqueous outflow and providing a significant and sustained decrease in IOP.